Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01775930|
Recruitment Status : Completed
First Posted : January 25, 2013
Last Update Posted : May 13, 2019
The goal of this clinical research study is learn if carfilzomib can help control kidney cancer. The safety of this drug will also be studied.
Carfilzomib is designed to block cancer cells from repairing themselves. If the cancer cells cannot repair themselves, this may cause them to die.
|Condition or disease||Intervention/treatment||Phase|
|Kidney Cancer||Drug: Carfilzomib||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma|
|Actual Study Start Date :||October 2013|
|Actual Primary Completion Date :||January 18, 2019|
|Actual Study Completion Date :||January 18, 2019|
Patients receive Carfilzomib at dose of 20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
- Progression Free Survival (PFS) [ Time Frame: 8 weeks ]Progression free survival defined as time from enrollment to progression or death, whichever comes first. Progression defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Any patients who are alive and free of disease at time of analysis censored at date of most recent tumor assessment. Response defined as complete response or partial response by RECIST. Overall survival defined as time from enrollment to death, regardless of cause. Patients who are alive at time of analysis censored on date they were last in contact with study personnel.
- Safety of Carfilzomib Treatment in Patients with Metastatic Renal Cell Carcinoma (RCC) [ Time Frame: 8 weeks ]Adverse events recorded by Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0 with information regarding relationship to the study drug. Whether or not a patient had to be discontinued from therapy due to predefined severe toxicity also recorded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01775930
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Eric Jonasch, MD||M.D. Anderson Cancer Center|